Finance

Lists
LSTA:NASDAQ
Lisata Therapeutics, Inc.
$1.09
0.00%
(0.00) 1D
Nov 17, 11:39:03โ€ฏAM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for LSTA...
Open
$1.08
High
$1.10
Low
$1.00
Mkt. cap
11.78M
Avg. vol.
135.12K
Volume
224.85K
52-wk high
$5.06
52-wk low
$0.96
EPS
-$1.64
Beta
1.04
Shares outstanding
10.80M
No. of employees
21
Open
$1.08
High
$1.10
Low
$1.00
Mkt. cap
11.78M
Avg. vol.
135.12K
Volume
224.85K
52-wk high
$5.06
52-wk low
$0.96
EPS
-$1.64
Beta
1.04
Shares outstanding
10.80M
No. of employees
21
News stories
From web sources and news partners
Profile
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022. In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide. Wikipedia
About Lisata Therapeutics, Inc.
CEO-
Employees21
Founded1980
HeadquartersBasking Ridge, New Jersey, United States
SectorHealth Care
IndustryBiotechnology
Websitelisata.com
Analyst
Recommendation
Action
Price target
Projected
Date
Kemp Dolliver
Brookline Capital Markets
Hold
Downgraded
-
-
07/27/2026
Joseph Pantginis
H.C. Wainwright
Hold
Downgraded
-
-
05/18/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
100.00K
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
1.13M
1.20M
584.00K
5.21M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.04M
3.74M
3.41M
4.82M
Operating expense
3.18M
4.94M
3.99M
10.03M
Total operating expenses
3.18M
4.94M
3.99M
10.03M
Operating income
-3.08M
-4.94M
-3.99M
-10.03M
Other non operating income
-16.00K
-16.00K
984.00K
-3.06M
EBT including unusual items
-2.95M
-4.88M
-2.93M
-12.81M
EBT excluding unusual items
-2.95M
-4.84M
-2.93M
-12.81M
Income tax expense
-
-387.00K
-
-6.03M
Effective tax rate
-
7.94%
-
47.03%
Other operating expenses
-
-
-
-
Net income
-2.95M
-4.49M
-2.93M
-6.79M
Net profit margin
-2,954.00%
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
141.00K
120.00K
79.00K
273.00K
Interest expense
-
-
-
-
Net interest expenses
141.00K
120.00K
79.00K
273.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-3.06M
-4.94M
-3.99M
-10.03M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps